anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Blood hemoglobin is measured daily in clinical practice. Laboratory measurement (Lab-Hb) of is the gold standard for assessment of blood hemoglobin. Recently, non-invasive monitors had been introduced. Non-invasive measurement of hemoglobin (Sp-Hb) would save time and minimize the risk of infection. Blood sampling in children is usually more difficult and stressful; moreover, it also carries the risk of iatrogenic anemia.

Radical-7 (Masimo corporation, Irvine, CA) is a device that operates using the principle of co-oximetry . Radical-7 had been validated in various clinical purposes. Measurement of blood hemoglobin is an important application for Radical-7 device. Non-invasive hemoglobin (Sp-Hb) measurement has been frequently validated in adults; as well as in pediatric patients; however, its accuracy in children with congenital heart disease was not investigated. Congenital heart disease infants usually undergo major operations and frequently need transfusion of blood. Moreover, these patients have special circulatory physiology that might impact the device accuracy. It had been recently reported that the performance of co-oximetry in congenital heart disease children is poor in measurement of oxygen saturation specially at oxygen saturation under 75%; however, its accuracy in measurement of hemoglobin was not investigated yet. In this study, the investigators will evaluate the accuracy of Sp-Hb compared to traditional Lab-Hb in children with congenital heart disease. the investigators will also compare the accuracy of Sp-Hb in cyanotic children to acyanotic children.
B-1a cells, a regulatory subset of B lymphocytes, produce natural IgM and interleukin-10. Neutrophil extracellular traps (NETs) play a crucial role in pathogen defense, but their excessive formation during sepsis can cause further inflammation and tissue damage. In sepsis, extracellular cold-inducible RNA-binding protein (eCIRP), a damage-associated molecular pattern, is released to induce NET formation. We hypothesize that B-1a cells clear NETs to prevent sepsis-induced injury. Sepsis in mice was induced by injecting 1 × 107 and 5 × 107 colony-forming units of Escherichia coli intraperitoneally. After 4 and 20 h, we assessed the number of B-1a cells in the peritoneal cavity using flow cytometry. Our results showed that the number of peritoneal B-1a cells was significantly decreased in E. coli sepsis mice. Importantly, replenishing B-1a cells via intraperitoneal injection in sepsis mice significantly decreased NETs in peritoneal neutrophils. We also observed a decrease in serum inflammation and injury markers and a significant increase in the overall survival rate in B-1a cell-treated septic mice. To understand the mechanism, we cocultured bone marrow-derived neutrophils with peritoneal B-1a cells in a contact or noncontact condition using an insert and stimulated them with eCIRP. After 4 h, we found that eCIRP significantly increased NET formation in bone marrow-derived neutrophils. Interestingly, we observed that B-1a cells inhibited NETs by 67% in a contact-dependent manner. Surprisingly, when B-1a cells were cultured in inserts, there was no significant decrease in NET formation, suggesting that direct cell-to-cell contact is crucial for this inhibitory effect. We further determined that B-1a cells promoted NET phagocytosis, and this was mediated through natural IgM, as blocking the IgM receptor attenuated the engulfment of NETs by B-1a cells. Finally, we identified that following their engulfment, NETs were localized into the lysosomal compartment for lysis. Thus, our study suggests that B-1a cells decrease NET content in eCIRP-treated neutrophils and E. coli sepsis mice.
BACKGROUND: Chronic wounds have been associated with an elevated burden of cellular senescence, a state of essentially irreversible cell cycle arrest, resistance to apoptosis, and a secretory phenotype. However, whether senescent cells contribute to wound chronicity in humans remains unclear. The objective of this article is to assess the role of clinicopathological characteristics and cellular senescence in the time-to-healing of chronic wounds.
METHODS: A cohort of 79 patients with chronic wounds was evaluated in a single-center academic practice from February 1, 2005, to February 28, 2015, and followed for up to 36 months. Clinical characteristics and wound biopsies were obtained at baseline, and time-to-healing was assessed. Wound biopsies were analyzed histologically for pathological characteristics and molecularly for markers of cellular senescence. In addition, biopsy slides were stained for p16INK4a expression.
RESULTS: No clinical or pathological characteristics were found to have significant associations with time-to-healing. A Cox proportional hazard ratio model revealed increased CDKN1A (p21CIP1/WAF1) expression to predict longer time-to-healing, and a model adjusted for gender and epidermal hyperplasia revealed increased CDKN1A expression and decreased PAPPA expression to predict longer time-to-healing. Increased p16INK4a staining was observed in diabetic wounds compared to non-diabetic wounds, and the same association was observed in the context of high dermal fibrosis.
CONCLUSIONS: The findings of this pilot study suggest that senescent cells contribute to wound chronicity in humans, especially in diabetic wounds.
This is a prospective, single-arm, multicenter cohort study evaluating the efficacy, safety, and tolerability of TAF monotherapy in in Asian CHB adults with SOR to the nucleos(t)ide therapy by assessing the HBV DNA suppression in 48 weeks. Approximately one hundred adults who received the aforementioned nucleos(t)ide therapy will be prospectively enrolled during the period from December 2019 to June 2021. Subjects will be enrolled by medical clinic in about 10 university centers in different regions in China. Approximately 10-15 consecutive eligible patients will be enrolled from each participating sites. This study will be conducted in accordance with the guidelines of Good Clinical Practices (GCPs) including Institutional Review Board (IRB) approval and consent will be applied. Patient identification (ID) will be de-identified for submitting to the central database for analyses from all study sites. Free TAF treatment will be provided to all enrolled patients for 48 weeks. Patients will be under the local standard of care upon the completion of the current study.

Patients aged 18-80 with CHB infection who had received nucleos(t)ide therapy over 24 weeks of LAM/LdT/ADV or 48 weeks of ETV with medication adherence, but failure to achieve the levels of HBV-DNA below 300 IU/mL will be eligible. Subjects will be excluded if they meet the following criteria: co-infected with HIV or other viral hepatitis; the serum levels of HBV DNA are too low (i.e. about 300 IU/mL) to be analyzed for the genotypic mutation(s); nucleos(t)ide resistant mutants have been detected at screening visit, patient is under a clinical research protocol of phase I-III development; unable to consent or unlikely to complete one year follow up after the enrollment; and other medical condition may affect the ability to participate the study.
Outdoor cold air exposure (\<10°C or \<50°F) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
Monitoring of intraoperative core temperature is essential for patient safety, reducing the risk of perioperative hypothermia. A recently developed measuring system, SpotOn® (3M, St. Paul, MN), measures the core temperature in a non-invasive manner. Its accuracy in patients undergoing general surgery has not been investigated yet. The study was aimed at comparing the accuracy of the SpotOn® in comparison with the oesophageal probe which is considered the current standard in our care units. In this study, patients who were candidates for major or urological surgery will be considered eligible for enrollment. The core body temperature will be thus measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
The invention relates to injectable long-acting insulin foormulations for the treatment of types I and II diabetes in humans and animals. The essential object of the invention is to provide an injectable long-acting insulin formulation in the form of a colloidal suspension which is stable, which has a good local tolerance and toxicity compatible with the chronic treatment of diabetics, and which maintains a substantial hypoglycemic effect extending over at least 24 hours after a single administration, e.g. by the subcutaneous route. To achieve this object, the invention relates to a stable aqueous colloidal fon-nulation of insulin-laden nanopai-ticles of at least one poly(Leu-block-Glu) in which the pH is between 5.8 and 7.0, the osmolarity O (in mosmol) ... : 270 ≤ 0 ≤ 800, and the viscosity v (in mpa.s) is low, namely v ≤ 40. The nanoparticles of poly(Leu-block-Glu) have a mean hydrodynamic diameter Dh such that: 15 ≤ Dh ≤ 40. The invention relates to an antidiabetic drug based on this long-acting insulin formulation and injectable using needles of gauge 29G, 30G or 31G.
The present invention relates to a mucoadhesive layer. preferably mucoadhesive buccal layer, comprising a non-nanoparticulate macrolide. Furthermore, the present invention relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer comprising a non-nanoparticulate macrolide. and further comprising a backing layer. The present invention also relates to a mucoadhesive film. preferably mucoadhesive buccal film, comprising a mucoadhesive layer. a backing layer. and an intermediate layer. The present invention further relates to a mucoadhesive layer or mucoadhesive film for use as a medicament and for use in preventing and/or treating transplant rejection. Moreover. the present invention relates to a method of preparing a mucoadhesive film.
OBJECTIVE: Delayed onset muscle soreness (DOMS) can reduce joint range of motion and strength, cause edema, and increase joint stiffness. Here we set out to determine whether quadriceps DOMS followed by an active recovery low-intensity exercise alters jump landing biomechanics.
METHODS: 3D landing kinematics, kinetics, and DOMS were evaluated in 26 healthy adults (15 women) performing drop and vertical jump landings before and after a squat protocol to induce quadriceps DOMS. In the presence of DOMS, half of the participants (n = 13) performed a low-intensity exercise for active recovery (10-minute treadmill walking), while the other half (n = 13) did not. Descriptive statistics and generalized estimative equations were applied to determine the effects of DOMS and active recovery on landing kinematics and kinetics.
RESULTS: DOMS decreased knee and ankle flexion angles and increased knee and ankle frontal plane angles during vertical jumps. DOMS elicited a longer time to reach peak ground reaction force during drop jumps. Low-intensity exercise for active recovery reduced DOMS perception but did not alter the biomechanics of landing.
CONCLUSION: DOMS changes landing strategy. However, including a low-intensity exercise for active recovery before landing practice did not change the kinematics and kinetics of landing.
The invention provides an edible material used for beef breeding and having the effect of preventing beef parotitis. The edible material comprises radix scutellariae, mangnolia officinalis, folium ilicis chinensis, radix paeoniae rubra, gastrodia elata, dahurian patrinia herb, cortex phellodendri, roses, garden burnet, lotus rhizome nodes, snakegourd fruit, bighead atractylodes rhizome, honeysuckle, liquorice, orange peels, honey and an addition material. When the edible materials are used, a beef is fed with 3-5 kilograms of edible material each time three times to five times every day, after the beef is fed for three days, the swelling fades away, and after the beef is continuously fed for three days, the beef is healed and can normally eat grasses. A using method of the edible material is simple; the edible material has the effects of clearing away heat and toxic materials, coursing and dissipating wind evil and harmonizing the spleen and stomach and a good treatment effect on the beef parotitis. Beefs are not drenched and can eat the addition material voluntarily. The effective rate of the edible material for treating the parotitis is 91.6%.
The phytochemical content analysis of the Ononis natrix plant, also known as semisk, kayıskıran, and okuzcanı in Turkey, revealed that it has a rich phenolic compound content, mainly in terms of quercetin, apigenin, and luteolin. In studies with various animal models and in-vitro cell culture models, it has been shown that these compounds inhibit protein degradation in skeletal muscle that develops due to various reasons. Therefore, we tested whether O. natrix plant extracts themselves could inhibit protein degradation in a skeletal muscle cell culture model. Morphological and molecular analyzes have shown that O. natrix extracts significantly reduce protein degradation under cell culture conditions with an agent that stimulates protein degradation. All these findings show that O. natrix extracts have the potential to be an important preventive supplement or additive in all health problems that require the preservation of muscle function. Therefore, it is anticipated that Onanis natrix plant extracts can be used as a supplement to reduce the loss of skeletal muscle functions in cases where the protein content of skeletal muscle is degraded by aging or secondary to chronic diseases.
With ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shocks/session was applied in a single session with a 15 mm head. Shock waves will be applied directly to the most sensitive point detected in the medial calcaneus, then a tape consisting of 96% cotton and 4% lycra, water-resistant, porous and adhesive, 5 cm wide and 0.5 mm thick will be used. Taping will be done after the ESWT session and the tape will be asked to remain for a week.
The aim of this study was to describe three dogs with permanent fibular nerve injury following tibial plateau levelling osteotomy (TPLO). Fibular nerve injury following TPLO led to atrophy of the cranial tibial muscle, absent hock flexion and a mild lameness. Fibular nerve injury was confirmed in one case with electrodiagnostics. All three cases had a drill tract in the same location, on the caudal aspect of the tibia, immediately distal to the tibial osteotomy. Permanent fibular nerve injury following TPLO occurred with a more caudally positioned plate and care should be taken when drilling the tibia from medial to lateral in the region described. Careful gait assessment at routine follow-up was required to identify this complication.
Tomatoes are frequently challenged by various pathogens, among which Phytophthora capsici (P. capsici) is a destructive soil-borne pathogen that seriously threatens the safe production of tomatoes. Plant growth-promoting rhizobacteria (PGPR) positively induced plant resistance against multiple pathogens. However, little is known about the role and regulatory mechanism of PGPR in tomato resistance to P. capsici. Here, we identified a new strain Serratia plymuthica (S. plymuthica), HK9-3, which has a significant antibacterial effect on P. capsici infection. Meanwhile, stable colonization in roots by HK9-3, even under P. capsici infection, improved tomato growth parameters, root system architecture, photosynthetic capacity, and boosted biomass. Importantly, HK9-3 colonization significantly alleviated the damage caused by P. capsici infection through enhancing ROS scavenger ability and inducing antioxidant defense system and pathogenesis-related (PR) proteins in leaves, as evidenced by elevating the activities of peroxidase (POD), superoxide dismutase (SOD), catalase (CAT), ascorbate peroxidase (APX), phenylalanine ammonia lyase (PAL), polyphenol oxidase (PPO), and chitinase, β-1,3-glucanase, and increasing the transcripts of POD, SOD, CAT, APX1, PAL1, PAL2, PAL5, PPO2, CHI17 and β-1,3-glucanase genes. Notably, HK9-3 colonization not only effectively improved soil microecology and soil fertility, but also significantly enhanced fruit yield by 44.6% and improved quality. Our study presents HK9-3 as a promising and effective solution for controlling P. capsici infection in tomato cultivation while simultaneously promoting plant growth and increasing yield, which may have implications for P. capsici control in vegetable production.
Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2b may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, irinotecan will be administered every other week and cetuximab will be administered weekly.
BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.
CPT, a botanical anticancer drug, is a mechanism that inhibits DNA synthesis and thus exerts anticancer effects by using topoisomerase I as its target of action, and has shown good efficacy in digestive system tumors and head and neck tumors, etc. Previous research result showed that amphiphilic EB-ss-CPT formed nanoparticles by self-assembly, bound to albumin in vivo and released CPT by breaking disulfide bonds under high GSH conditions in tumor tissues, effectively enhancing the pharmacokinetics and biodistribution of camptothecin, thereby improving therapeutic efficacy and In this study, the sensitivity of colorectal cancer cells to the drug was also demonstrated. In this study, 64Cu-NOTA-EB-ss-CPT (hereafter 64Cu-EB-CPT) was generated by posionuclide 64Cu-labelled EB-ss-CPT for PET/CT imaging alone and showed better tumour enrichment compared to the 64Cu-labelled CPT group. EB-CPT is expected to be more enriched in tumour tissue through the EPR effect of its nanoparticles, and 64Cu is also a promising radionuclide for quantitative analysis using PET/CT imaging. The formation of 64Cu-EB-CPT or 68Ga-EB-CPT by labelling EB-CPT with the positronium nuclide 64Cu or 68Ga is expected to be enhanced by the EPR effect of the precursors (the enhanced permeability and retention effect of solid tumours). The EPR effect (enhanced permeability and retention effect) refers to the tendency of molecules or particles of certain sizes to accumulate in tumour tissue relative to normal tissue) is expected to enrich the drug in the tumour area and allow early diagnosis of tumour patients by PET/CT imaging with the preceding positronuclide 64Cu or 68Ga, which can help in the staging of tumours and the development of treatment plans.
This invention relates to "targeted" viral or non-viral vector particles, including retroviral vector particles, adenoviral vector particles, adeno-associated virus vector particles, Herpes Virus vector particles, and pseudotyped viruses, and to non-viral vectors that contain a viral protein as part of a virosome or other proteoliposomal gene transfer vector. More particularly, this invention relates to viral and non-viral vector particles, including retroviral vector particles, adenoviral vector particles, adeno-associated virus vector particles, Herpes Virus vector particles, pseudotyped viruses, and non-viral vectors having a modified, or chimeric viral surface protein, such as, for example, a chimeric viral envelope polypeptide, wherein such modified viral surface protein, such as a modified viral envelope polypeptide, includes a peptide which is a tumor vasculature targeting motif or TVTM. The TVTM peptide may be placed between two consecutive amino acid residues of the viral surface protein, or may replace amino acid residues which have been removed from the viral surface protein. The term "polypeptide" as used herein means a polymer of amino acids and does not refer to any particular length of polymer. Such term also includes post-translationally modified polypeptides or proteins (e.g., glycosylated, acetylated, phosphorylated, etc.).
An apparatus is provided for managing clinical information. The apparatus may include at least one memory and at least one processor configured to automatically receive one or more items of clinical information, corresponding to respective patients, from different sources. The processor is also configured to detect an indication of a comparison indicating whether medications identified in the clinical information were utilized by the patients as prescribed by a health care provider(s). The processor is also configured to generate a user interface including visible indicia indicating medications prescribed to respective patients and statuses of the medications. The statuses may be designated responsive to determining that one or more respective items of the clinical information is newly received from one of the different sources or based in part on the comparison indicating whether the medications were utilized by the patients as prescribed. Corresponding computer program products and methods are also provided.
The invention provides health-preservation healthcare liquor and a preparation method thereof. The health-preservation healthcare liquor is prepared from the following raw materials in weight ratio: 50-150 of wheat bran yeast liquor, 50-150 of fermented glutinous rice yeast liquor, 100-150 of table vinegar, 50-100 of honey, 50-100 of Chinese wolfberry, 25-50 of maltose and 50-100 of glucose. The preparation method of the health-preservation healthcare liquor comprises the following steps of: sequentially adding the raw materials prepared in weight ratio to a container, standing and soaking for 24-48 hours, filtering and bottling to obtain the health-preservation healthcare liquor. Compared with the prior art, the health-preservation healthcare liquor has a good curative effect on osteoproliferation without toxic or side effects. The preparation method is simple and low in cost. The observation of curative effects shows that the effective rate for treating the osteoproliferation is above 95%, and the obvious effective rate is above 80%.
PCT No. PCT/JP95/01995 Sec. 371 Date Aug. 9, 1996 Sec. 102(e) Date Aug. 9, 1996 PCT Filed Sep. 29, 1995 PCT Pub. No. WO96/18375 PCT Pub. Date Jun. 20, 1996A composition for rouge for lip of the present invention is a composition for rouge for lip containing a volatile oil content, a water-repellent polymer soluble to the volatile oil content, powder, and a nonvolatile oil content having a compatibility with the volatile oil content, wherein the powder contained in 1 g of the composition has a total surface arm of 1 to 25 m2. According to the composition for rouge for lip of the present invention, a composition for rouge for lip in which the secondary adhesion is improved and feel of use is excellent can be obtained.